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Bio-Medical
Tissue Engineering Using Transfected Growth-Factor Genes
Cells, matrices, and bioreactors are tailored to promote functional tissue engineering of cartilage.
Lyndon B. Johnson Space Center, Houston, Texas
A method of growing bioengineered
tissues includes, as a major component,
the use of mammalian cells that have
been transfected with genes for secretion
of regulator and growth-factor sub-
stances. In a typical application, one ei-
ther seeds the cells onto an artificial ma-
trix made of a synthetic or natural
biocompatible material, or else one cul-
tures the cells until they secrete a desired
amount of an extracellular matrix. If
such a bioengineered tissue construct is
to be used for surgical replacement of in-
jured tissue, then the cells should prefer-
ably be the patient’s own cells or, if not,
at least cells matched to the patient’s
cells according to a human-leucocyte-
antigen (HLA) test. The bioengineered
tissue construct is typically implanted in
the patient’s injured natural tissue,
wherein the growth-factor genes en-
hance metabolic functions that promote
the in vitro development of functional tis-
sue constructs and their integration with
native tissues. If the matrix is biodegrad-
able, then one of the results of metabo-
lism could be absorption of the matrix
and replacement of the matrix with tis-
sue formed at least partly by the trans-
fected cells.
The method was developed for articu-
lar chondrocytes but can (at least in
principle) be extended to a variety of
cell types and biocompatible matrix ma-
terials, including ones that have been ex-
ploited in prior tissue-engineering meth-
ods. Examples of cell types include
chondrocytes, hepatocytes, islet cells,
nerve cells, muscle cells, other organ
cells, bone- and cartilage-forming cells,
epithelial and endothelial cells, connec-
tive-tissue stem cells, mesodermal stem
cells, and cells of the liver and the pan-
creas. Cells can be obtained from cell-
line cultures, biopsies, and tissue banks.
Genes, molecules, or nucleic acids that
secrete factors that influence the growth
of cells, the production of extracellular
matrix material, and other cell functions
can be inserted in cells by any of a vari-
ety of standard transfection techniques.
The method was developed for polyg-
lycolic acid scaffolds, but can (at least in
principle) be extended to other
biodegradable matrix materials, which
include collagen, fibrin, and poly(lactic
acid) [PLA], poly(glycolic acid) [PGA],
and PLA/PGA copolymers. Non-
biodegradable matrix materials include
polystyrene, polyesters, polypropylene,
and numerous other polymers. Prefer-
ably, the matrix for a given therapeutic
application should be fabricated so as
to have a microstructure similar to that
of the extracellular matrix to be re-
placed. Mechanical loads imposed on
the matrix by the surrounding tissue in-
fluence the cells on and in the matrix
in such a manner as to promote the re-
generation of an extracellular matrix
that has the proper microstructure.
The cross-link density of the matrix can
be tailored in fabrication in order to
tailor the mechanical properties of the
matrix and, in the case of a biodegrad-
able matrix, to tailor the rate of its
biodegradation. The shape and size of
the matrix and the implant made from
it should, of course, be chosen to suit
the implant site and tissue type. The
matrix material can be coated with ma-
terials that promote specific adhesion
and metabolic behavior of both trans-
fected cells and native cells.
Another important consideration in the
design of a matrix is porosity. Pores must be
large enough that cells can reside within
them and that nutrients can migrate to the
cells and waste products can diffuse away
from the cells. Typical pore sizes range
from 50 to 300 µm; the size or range of sizes
can be chosen to obtain the cell behavior
and matrix properties desired for a given
application. Moreover, the range of pore
sizes for a given application can be chosen
to promote a specific timetable and
amount of vascular ingrowth from the sur-
rounding tissue as well as migration of na-
tive cells.
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Automation of Vapor-Diffusion Growth of Protein Crystals
High-throughput experiments are accelerated through automation of routine operations.
Marshall Space Flight Center, Alabama
Some improvements have been made
in a system of laboratory equipment devel-
oped previously for studying the crystal-
lization of proteins from solution by use of
dynamically controlled flows of dry gas.
The improvements involve mainly (1) au-
tomation of dispensing of liquids for start-
ing experiments, (2) automatic control of
drying of protein solutions during the ex-
periments, and (3) provision for auto-
mated acquisition of video images for
monitoring experiments in progress and
for post-experiment analysis.
The automation of dispensing of liq-
uids was effected by adding an automated
liquid-handling robot that can aspirate
source solutions and dispense them in ei-
ther a hanging-drop or a sitting-drop con-
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